A phase I trial to assess first line therapy with sunitinib, in combination with gemcitabine + capecitabine, in patients with metastatic, or unresectable, renal cell carcinoma

Trial Profile

A phase I trial to assess first line therapy with sunitinib, in combination with gemcitabine + capecitabine, in patients with metastatic, or unresectable, renal cell carcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Sunitinib (Primary) ; Capecitabine; Gemcitabine
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top